Quantcast

Latest Peptides Stories

2011-05-22 00:02:21

American Peptide Company, a leading innovator in peptide manufacturing and peptide-based services, is offering cost-effective, high-quality stable isotope labeled peptides for use as quantitative standards, and for structural analysis. Sunnyvale, CA (PRWEB) May 20, 2011 American Peptide Company, a leading innovator in peptide manufacturing and peptide-based services, is offering cost-effective, high-quality stable isotope labeled peptides for use as quantitative standards, and for...

2011-05-10 02:03:00

PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/ -- Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery. Under the terms of the agreement, Pepscan using its...

2011-04-04 08:00:00

LELYSTAD, The Netherlands, April 4, 2011 /PRNewswire/ -- Pepscan Therapeutics, the Dutch biotech company focusing on protein mimicry for the discovery of therapeutics peptides and antibodies, announced today the appointment of Michiel Lodder as Chief Business Officer. Dr. Lodder joins Pepscan from Octoplus, where he held the position of Senior Manager Business Development, responsible for licensing, partnering, and alliance management activities. "We are delighted to bring Michiel...

2011-03-30 15:05:00

PALO ALTO, Calif., March 30, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 10th Annual Needham Healthcare Conference in New York City on Wednesday, April 6 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time), in the New York Palace Hotel's Henry's Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2011-03-30 09:17:00

BASKING RIDGE, N.J., March 30, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Needham & Company's 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, April 6, 2011 at 11:20 a.m. EDT. The presentation will include an overview of the Company's pipeline with emphasis...

2011-03-30 06:00:00

SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming cenderitide presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5th. Location: Ernest N. Morial Convention Center, Hall FDate: Sunday, April 3, 2011Time: 10:00 AM -11:15 AM (CDT)Poster Presentation: Board #256...

2011-03-28 11:09:00

BASKING RIDGE, N.J., March 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific...

2011-03-21 06:00:00

DUBLIN and LEXINGTON, Massachusetts, March 21, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline...

2011-03-03 05:59:00

DUBLIN and LEXINGTON, Massachusetts, March 3, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the European Commission has approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. FIRAZYR is the first and only treatment for acute Type I and Type II hereditary angioedema (HAE) attacks licensed for self-administration in Europe. "Given...

2011-03-02 01:59:54

In the face of the growing obesity epidemic, much research has focused on the neuronal control of feeding behavior. Agouti-related protein (AgRP) neurons express three proteins that have been implicated in changes in energy balance, but the studies linking AgRP neurons to feeding behavior have produced mixed results. To directly analyze the role of AgRP neurons, Bradford Lowell and colleagues, at Beth Israel Deaconess Medical Center in Boston, used DREADD technology (designer receptors...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related